Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.

Lawlor B, Segurado R, Kennelly S, Olde Rikkert MGM, Howard R, Pasquier F, Börjesson-Hanson A, Tsolaki M, Lucca U, Molloy DW, Coen R, Riepe MW, Kálmán J, Kenny RA, Cregg F, O'Dwyer S, Walsh C, Adams J, Banzi R, Breuilh L, Daly L, Hendrix S, Aisen P, Gaynor S, Sheikhi A, Taekema DG, Verhey FR, Nemni R, Nobili F, Franceschi M, Frisoni G, Zanetti O, Konsta A, Anastasios O, Nenopoulou S, Tsolaki-Tagaraki F, Pakaski M, Dereeper O, de la Sayette V, Sénéchal O, Lavenu I, Devendeville A, Calais G, Crawford F, Mullan M; NILVAD Study Group.

PLoS Med. 2018 Sep 24;15(9):e1002660. doi: 10.1371/journal.pmed.1002660. eCollection 2018 Sep.

2.

European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease-the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow.

Meulenbroek O, O'Dwyer S, de Jong D, van Spijker G, Kennelly S, Cregg F, Olde Rikkert M, Abdullah L, Wallin A, Walsh C, Coen R, Kenny RA, Daly L, Segurado R, Borjesson-Hanson A, Crawford F, Mullan M, Lucca U, Banzi R, Pasquier F, Breuilh L, Riepe M, Kalman J, Molloy W, Tsolaki M, Howard R, Adams J, Gaynor S, Lawlor B.

BMJ Open. 2016 Jul 19;6(7):e011584. doi: 10.1136/bmjopen-2016-011584.

3.

NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease.

Lawlor B, Kennelly S, O'Dwyer S, Cregg F, Walsh C, Coen R, Kenny RA, Howard R, Murphy C, Adams J, Daly L, Segurado R, Gaynor S, Crawford F, Mullan M, Lucca U, Banzi R, Pasquier F, Breuilh L, Riepe M, Kalman J, Wallin A, Borjesson A, Molloy W, Tsolaki M, Olde Rikkert M.

BMJ Open. 2014 Oct 9;4(10):e006364. doi: 10.1136/bmjopen-2014-006364. Erratum in: BMJ Open. 2015;5(9):e006364.

4.

Reasons that prevent the inclusion of Alzheimer's disease patients in clinical trials.

Rollin-Sillaire A, Breuilh L, Salleron J, Bombois S, Cassagnaud P, Deramecourt V, Mackowiak MA, Pasquier F.

Br J Clin Pharmacol. 2013 Apr;75(4):1089-97. doi: 10.1111/j.1365-2125.2012.04423.x.

5.

Toll-like receptor (TLR)2 and TLR3 synergy and cross-inhibition in murine myeloid dendritic cells.

Vanhoutte F, Paget C, Breuilh L, Fontaine J, Vendeville C, Goriely S, Ryffel B, Faveeuw C, Trottein F.

Immunol Lett. 2008 Feb 15;116(1):86-94. doi: 10.1016/j.imlet.2007.11.014. Epub 2007 Dec 17.

PMID:
18166232
6.

Toll-like receptor (TLR)2 and TLR3 sensing is required for dendritic cell activation, but dispensable to control Schistosoma mansoni infection and pathology.

Vanhoutte F, Breuilh L, Fontaine J, Zouain CS, Mallevaey T, Vasseur V, Capron M, Goriely S, Faveeuw C, Ryffel B, Trottein F.

Microbes Infect. 2007 Nov-Dec;9(14-15):1606-13. Epub 2007 Sep 26.

PMID:
18023390
7.

Galectin-3 modulates immune and inflammatory responses during helminthic infection: impact of galectin-3 deficiency on the functions of dendritic cells.

Breuilh L, Vanhoutte F, Fontaine J, van Stijn CM, Tillie-Leblond I, Capron M, Faveeuw C, Jouault T, van Die I, Gosset P, Trottein F.

Infect Immun. 2007 Nov;75(11):5148-57. Epub 2007 Sep 4.

8.

Invariant and noninvariant natural killer T cells exert opposite regulatory functions on the immune response during murine schistosomiasis.

Mallevaey T, Fontaine J, Breuilh L, Paget C, Castro-Keller A, Vendeville C, Capron M, Leite-de-Moraes M, Trottein F, Faveeuw C.

Infect Immun. 2007 May;75(5):2171-80. Epub 2007 Mar 12.

9.

Impact of bronchial epithelium on dendritic cell migration and function: modulation by the bacterial motif KpOmpA.

Pichavant M, Taront S, Jeannin P, Breuilh L, Charbonnier AS, Spriet C, Fourneau C, Corvaia N, Héliot L, Brichet A, Tonnel AB, Delneste Y, Gosset P.

J Immunol. 2006 Nov 1;177(9):5912-9.

10.

Specific recognition of Candida albicans by macrophages requires galectin-3 to discriminate Saccharomyces cerevisiae and needs association with TLR2 for signaling.

Jouault T, El Abed-El Behi M, Martínez-Esparza M, Breuilh L, Trinel PA, Chamaillard M, Trottein F, Poulain D.

J Immunol. 2006 Oct 1;177(7):4679-87.

Supplemental Content

Loading ...
Support Center